StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a report released on Saturday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Up 1.3 %
Shares of NASDAQ TTNP opened at $4.42 on Friday. Titan Pharmaceuticals has a 12 month low of $3.57 and a 12 month high of $14.80. The business’s 50 day moving average is $4.92 and its two-hundred day moving average is $5.75.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last announced its earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Read More
- Five stocks we like better than Titan Pharmaceuticals
- With Risk Tolerance, One Size Does Not Fit All
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- What Makes a Stock a Good Dividend Stock?
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- Top Stocks Investing in 5G Technology
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
